{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-054513","form_type":"8-K","ticker":"ADPT","cik":"0001478320","company_name":"Adaptive Biotechnologies Corp","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.595591+00:00","generated_at":"2026-06-02T17:35:33.424824+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Adaptive Biotechnologies Q1 2024: MRD revenue up 52% to $32.6M; net loss narrows to $47.5M","bullets":["Total revenue $41.9M (+11% YoY); MRD $32.6M (+52%), Immune Medicine $9.2M (-43%).","clonoSEQ test volume rose 41% to 17,040; net loss improved to $47.5M from $57.7M.","Cash $308.9M; FY2024 MRD revenue guidance raised to $135-140M, opex lowered to $350-360M.","FDA ODAC unanimously supported MRD as primary endpoint for accelerated approval in multiple myeloma.","Strategic move: MRD and Immune Medicine to report separately; antibody discovery launched for MS and type 1 diabetes."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-054513","json":"https://secwatch.observer/filing/0000950170-24-054513.json","markdown":"https://secwatch.observer/filing/0000950170-24-054513.md","text":"https://secwatch.observer/filing/0000950170-24-054513.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1478320/000095017024054513/0000950170-24-054513-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1478320/000095017024054513/adpt-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T17:35:33.424824+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"27f970df66bb6a17e22bec3b7d0ed110ccd86ecd","claim":"Adaptive Biotechnologies Corp reported quarter ended March 31, 2024 results: revenue $41.9 million, net income $47.5 million loss.","evidence_excerpt":"First Quarter 2024 Financial Results Revenue was $41.9 million for the quarter ended March 31, 2024, representing an 11% increase from the first quarter in the prior year. MRD revenue was $32.6 million for the quarter, representing a 52% increase from the first quarter in the prior year. Immune Medicine revenue was $9.2 million for the quarter, representing a 43% decrease from the first quarter in the prior year. Operating expenses were $90.6 million for the first quarter of 2024, compared to $94.8 million in the first quarter of the prior year, representing a decrease of 4%. MRD operating expenses were $59.9 million for the quarter, representing a 7% increase from the first quarter in the prior year. Immune Medicine operating expenses were $23.8 million for the quarter, representing a 25% decrease from the first quarter in the prior year. Interest and other income, net was $4.2 million for the first quarter of 2024, compared to $3.0 million in the first quarter of the prior year. Inte","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1478320/000095017024054513/0000950170-24-054513-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2024"},{"label":"Revenue","value":"$41.9 million"},{"label":"Net income","value":"$47.5 million loss"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"a6463a8a06b6ea94b1bcd2c945e076840c76e54c","claim":"Adaptive Biotechnologies Corp updated its full year 2024 guidance (lowered).","evidence_excerpt":"Adaptive Biotechnologies expects full year revenue for the MRD business to be between $135 million and $140 million, updated from the previous range between $130 million and $140 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1478320/000095017024054513/0000950170-24-054513-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2024"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"a6463a8a06b6ea94b1bcd2c945e076840c76e54c","claim":"Adaptive Biotechnologies Corp updated its full year 2024 guidance (lowered).","evidence_excerpt":"We expect full year total company operating expenses, including cost of revenue, to be between $350 million and $360 million, updated from the previous range between $360 million and $370 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1478320/000095017024054513/0000950170-24-054513-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2024"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}